- Companies
- Akura Medical
Akura Medical Funding, Investors & Competitors
Akura Medical has raised $113M across 3 funding rounds, most recently a $53M Series C in December 2025.
Last Akura Medical funding round
$53M
Series C · Dec 2025
Cumulative funding Akura Medical raised
$113M
across 3 funding rounds
Key investors in Akura Medical
Cormorant Asset Management
The Capital Partnership
Shifamed
Lilly Asia Ventures
Qatar Investment Authority
AMED Ventures
Unorthodox Ventures
MedTech Venture Partners
About Akura Medical
Akura Medical is a Los Altos, California-based medical device company developing tools for venous thromboembolism treatment. Its Katana Thrombectomy System employs a steerable catheter with jet technology for clot disruption and removal in pulmonary embolism cases. NavIQ software generates 3D models from CT angiograms to visualize clot morphology and plan procedures.
Founded
2019
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Product sales, Subscription
Akura Medical Funding History
Akura Medical has raised a total of $113M across 3 funding rounds.
Akura Medical's first fundraising round was a $25M Series A in January 2022. The most recent completed round was a $53M Series C in December 2025.
Akura Medical funding rounds
| Date | Stage | Investors | Raised | Deal Summary |
|---|---|---|---|---|
| Dec 2025 | Series C | Qatar Investment Authority (lead) | $53M | Akura Medical, a Shifamed portfolio company based in Los Gatos, California, develops technologies for venous thromboembolism (VTE) care, including the investigational Katana thrombectomy system and NavIQ quantification software. The Katana system uses high-velocity saline jets to break up diverse clot types, prevent catheter clogging, and provide real-time pulmonary artery pressure data via sensors. NavIQ converts CT angiograms into 3D pulmonary models for procedural planning, clot characterization, and treatment prioritization. On December 1, 2025, Akura Medical announced a $53 million first close in its Series C financing round, led by Qatar Investment Authority with participation from existing investors. The funds will support development of the Katana system and NavIQ software, completion of enrollment in the QUADRA-PE clinical trial (which received FDA investigational device exemption in November 2024 and began enrolling in February 2025), and regulatory submissions. Part of the proceeds will establish a joint venture in Qatar to support international expansion. This Series C follows a $35 million Series B in 2023 led by The Capital Partnership and Cormorant Asset Management, and a $25 million round in 2022. Akura aims to address the unmet need in VTE treatment, which affects hundreds of thousands of U.S. patients annually, by advancing intelligent, data-driven thrombectomy solutions to improve procedural precision and patient outcomes. The Katana system remains for investigational use only and is not cleared for sale in the USA or approved in any country. |
| Oct 2023 | Series B | Cormorant Asset Management (lead); The Capital Partnership (lead); Shifamed; Lilly Asia Ventures; AMED Ventures; Unorthodox Ventures; PA MedTech VC Fund | $35M | Akura Medical is a Shifamed portfolio company developing technologies for venous thromboembolism (VTE) treatment, including the Akura Mechanical Thrombectomy Platform and later the Katana Thrombectomy System aimed at efficient clot removal across various clot types. The company closed a $35 million Series B financing round on October 3, 2023, led by The Capital Partnership and Cormorant Asset Management, with participation from PA MedTech VC Fund, AMED Ventures, Lilly Asia Ventures, Unorthodox Ventures, and Shifamed angel investors. Funds were allocated to pursue FDA 510(k) clearance for the thrombectomy platform, support clinical trials for additional indications, and scale manufacturing. This Series B followed a $25 million round in 2022, bringing total funding to around $60 million by late 2023. Akura's focus addresses challenges in VTE care, such as pulmonary embolism, with procedural planning tools like NavIQ software introduced later to convert CT angiograms into 3D models of pulmonary vessels. The company participated in events like the VIVA Foundation conference in October 2023. In a subsequent Series C round closed December 1, 2025, Akura raised $53 million led by Qatar Investment Authority, supporting Katana system development, QUADRA-PE study enrollment, regulatory submissions, NavIQ advancement, and a joint venture in Qatar. Total funding reached $113 million by then. |
| Jan 2022 | Series A | Cormorant Asset Management (lead); Shifamed; MedTech Venture Partners; The Capital Partnership | $25M | Akura Medical is a Shifamed portfolio company developing mechanical thrombectomy devices for venous thromboembolism (VTE), including pulmonary embolism (PE) and deep vein thrombosis (DVT). The company closed a $25 million Series A1 financing round on January 10, 2022, led by Cormorant Asset Management, with participation from The Capital Partnership, PA MedTech VC Fund, and Shifamed angel investors. The funds supported development of its next-generation thrombectomy device designed to simplify procedures and efficiently remove blood clots, addressing limitations in existing treatments. A PDF from Akura states the company had raised $27 million total between its seed and Series A rounds by mid-2023, aligning with the 2022 A1 round as part of early funding. Investors validated the technology's potential in an underserved VTE market. Subsequent rounds included a $35 million Series B in October 2023 led by The Capital Partnership and Cormorant, funding FDA clearance, clinical trials, and manufacturing. A $53 million Series C first close in December 2025 was led by Qatar Investment Authority, supporting the Katana Thrombectomy System, NavIQ software, QUADRA-PE trial, and a Qatar joint venture. An investigational device exemption for Katana in PE was granted in November 2024, with trial enrollment starting February 2025. The market shows low penetration rates (20% for DVT, 15% for PE), indicating significant opportunity. |
Who has invested in Akura Medical?
9 investors have backed Akura Medical across its funding rounds, including Cormorant Asset Management, The Capital Partnership, Shifamed, Lilly Asia Ventures, Qatar Investment Authority and AMED Ventures.
Lead investors include Qatar Investment Authority, Cormorant Asset Management and The Capital Partnership.
Akura Medical Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 2 | Participant | Jan 2022 | ||
| 2 | Lead | Jan 2022 | ||
| 2 | Lead | Jan 2022 | ||
| 1 | Participant | Jan 2022 | ||
| 1 | Lead | Dec 2025 | ||
| 1 | Participant | Oct 2023 | ||
| 1 | Participant | Oct 2023 | ||
This data is available for Pro users. Sign up to see all 9 Akura Medical investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAkura Medical Competitors
Akura Medical competitors include listed companies like GE HealthCare, United Imaging, Agilent and Glaukos, and private ones like Carestream and SiBionics.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Publicly listed | $21B | $3.7B | $29B | 1.8x | ||
| Publicly listed | $2.1B | $367M | $12B | 4.8x | ||
| Private | - | - | $800M | - | ||
| Private | - | - | $717M | - | ||
| Publicly listed | $6.9B | $1.8B | $44B | 6.2x | ||
| Publicly listed | $507M | ($157M) | $9.5B | 14.6x |
Akura Medical Public Comps
Akura Medical is still privately-owned, but its public comps include Samsung, Johnson & Johnson, Roche, Thermo Fisher Scientific, Siemens, Abbott, Danaher, Intuitive Surgical, Medtronic and Stryker.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $243B | $67B | 4.4x | 2.4x | 15.8x | 4.4x | |||
| $94B | $40B | 7.2x | 6.8x | 17.0x | 18.3x | |||
| $77B | $26B | 5.0x | 4.9x | 14.6x | 12.4x | |||
| $45B | $11B | 6.3x | 6.0x | 26.8x | 23.6x | |||
| $91B | $15B | 3.0x | 2.9x | 18.1x | 15.7x | |||
| $44B | $12B | 4.6x | 4.2x | 17.4x | 15.8x | |||
| $25B | $6.9B | 7.0x | 6.6x | 24.8x | 21.1x | |||
| $10B | $3.6B | 13.0x | 11.6x | 36.6x | 25.7x | |||
This data is available for Pro users. Sign up to see all Akura Medical competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Akura Medical
| When was Akura Medical founded? | Akura Medical was founded in 2019. |
| Where is Akura Medical headquartered? | Akura Medical is headquartered in San Jose, CA, United States. |
| Is Akura Medical publicly listed? | No, Akura Medical is a private, VC-backed company. |
| How much funding has Akura Medical raised? | Akura Medical has raised $113M across 3 funding rounds. |
| What was Akura Medical's last funding round? | Akura Medical's last funding round was a $53M Series C in December 2025, led by Qatar Investment Authority. |
| Who are Akura Medical's investors? | Akura Medical's investors include Shifamed, The Capital Partnership, Cormorant Asset Management, MedTech Venture Partners, Qatar Investment Authority, Lilly Asia Ventures, AMED Ventures, Unorthodox Ventures and PA MedTech VC Fund. |
| Which companies are comparable to Akura Medical? | Companies comparable to Akura Medical include GE HealthCare, United Imaging, Carestream, SiBionics, Agilent and Glaukos. |
See companies similar to Akura Medical
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




